Company news
VivoSim Labs, Inc. news in 2025
VivoSim Labs, Inc.'s news releases, calls and decks from 2025, newest first.
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
August 14, 2025
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
May 13, 2025
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
May 7, 2025
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
April 24, 2025
VivoSim to Carry Forward Organovo 3D Bioprinting
April 22, 2025
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
April 1, 2025
Organovo Provides Business Update
March 26, 2025
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
March 24, 2025
Organovo Announces Reverse Stock Split
March 18, 2025
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
March 5, 2025
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
February 24, 2025
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
January 5, 2025